Description: This product is a compound preparation, the group is divided into: piracetam (C6H10N2O2), sodium chloride. This product is the main ingredient Piracetam. Its chemical name: 2 - oxidation -1 - pyrrolidinyl acetamide. Excipients: sodium chloride, water for injection. This product is colorless transparent liquid.

Pharmacological effects: This product is brain metabolism improve drug piracetam belongs to the ring derivatives of γ-aminobutyric acid. Anti-physical factors, chemical factors in brain function caused by the injury. The promotion of brain ATP can promote the synthesis of acetylcholine and enhance the conduction of nerve excitability, with the promotion of brain metabolism. Against brain dysfunction caused by physical factors, chemical factors. Improve the role of the hypoxia-induced retrograde amnesia. Can enhance memory, improve learning ability.

Pharmacokinetics: Piracetam after oral administration. This product is quickly absorbed from the digestive tract into the blood through the blood-brain barrier to reach the brain and cerebrospinal fluid, cerebral cortex and olfactory bulb the concentration than the brain stem in higher concentrations. Easily through the placenta barrier. After oral administration, 30 to 45 minutes plasma concentration peak, plasma protein binding rate of 30%, half-life (t1/2) for 5 to 6 hours. Distribution capacity to 0.6L/Kg. piracetam can not be decomposed by the liver after oral administration, unchanged in form from the urine and faeces excretion. The renal clearance rate of 86ml/minute. stool about 1% to 2%.

Indications: For the treatment of intracranial hypertension caused by traumatic brain injury.

Precautions: Liver and kidney dysfunction who caution and should decrease the dose. Pregnant women and lactating women, pregnant and lactating women disabled. Pediatric Use preterm children, newborn disabled, halve the amount of children or as directed. Geriatric medicine based on the reduction of liver and kidney function to use or as directed. drug interactions of this product with warfarin in combination, prolong prothrombin time, induced inhibition of platelet aggregation. Special attention to the clotting time in patients receiving anticoagulant therapy, application of piracetam should be to prevent the risk of bleeding, and adjust the drug dosage and usage of anticoagulant therapy.

Adverse reaction: may have dry mouth, loss of appetite, hives and decreased memory thinking and reaction. Rare excitement, irritability, dizziness, headache and insomnia, occasional mild aminotransferase increases.